11/8/2022 8:13:17 AM
Akari Therapeutics Names John Neylan EVP, Chief Medical Officer
7/20/2022 6:07:11 AM
Akari Therapeutics Posts Q1 Breakeven Per Share, Flat With Last Year
4/12/2021 11:00:13 AM
Akari Therapeutics Initiates Pivotal Phase III Trial Of Nomacopan In Bullous Pemphigo
5/12/2017 6:47:50 AM
William Blair Downgrades Akari Therapeutics Plc (AKTX) To Market Perform From Outperform
4/6/2017 7:11:21 AM
William Blair Initiates Akari Therapeutics Plc (AKTX) At Outperform